Biogroup - comment - 26Q3
The Q3 results are unlikely to impact trading levels, with revenue 2% ahead and EBITDA 9% ahead of our forecast. EBITDA outperformance was driven by lower expenses, which more than offset higher staff costs. We misjudged working capital, resulting in FCF of €76.3m versus our €16.3m forecast. Capex of €40.3m was higher than expected, but mainly a timing issue. The company issued more upbeat guidance for Q426 and reassured the market regarding FY27.
Our concern remains the pricing environment in France. The new three-year agreement provides greater visibility, but acknowledges downward pressure on pricing. The agreement limits annual growth in routine medical biology expenditure to 1.1%, against underlying volume growth estimated at 3–3.5%, implying further tariff reductions to keep expenditure within the agreed envelope. Laboratory representatives are anticipating a 2–2.5% reduction in 2027. While volume growth and Biogroup's transformation programme should provide some offset, the market remains structurally challenged. At 7% yield, we are not convinced investors are adequately compensated.